Fate Therapeutics

๐Ÿ‡บ๐Ÿ‡ธUnited States
Ownership
-
Employees
220
Market Cap
$408.8M
Website

Single Treatment With FT1050 of an Ex-vivo Modulated Umbilical Cord Blood Unit

First Posted Date
2012-02-07
Last Posted Date
2016-09-12
Lead Sponsor
Fate Therapeutics
Target Recruit Count
10
Registration Number
NCT01527838
Locations
๐Ÿ‡บ๐Ÿ‡ธ

Massachusetts General Hospital, Boston, Massachusetts, United States

๐Ÿ‡บ๐Ÿ‡ธ

Dana Farber Cancer Institute-Hematopoietic Stem Cell Transplant Program, Boston, Massachusetts, United States

๐Ÿ‡บ๐Ÿ‡ธ

Ohio State Univeristy Comprehensive Cancer Center, Columbus, Ohio, United States

Safety and Efficacy of ProHema Modulated Umbilical Cord Blood Units in Subjects With Hematologic Malignancies.

First Posted Date
2009-04-29
Last Posted Date
2013-10-08
Lead Sponsor
Fate Therapeutics
Target Recruit Count
12
Registration Number
NCT00890500
Locations
๐Ÿ‡บ๐Ÿ‡ธ

Massachusetts General Hospital, Boston, Massachusetts, United States

๐Ÿ‡บ๐Ÿ‡ธ

Dana-Farber Cancer Institute, Boston, Massachusetts, United States

ยฉ Copyright 2024. All Rights Reserved by MedPath